Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kleanthous, H.
Right arrow Articles by Monath, T. P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kleanthous, H.
Right arrow Articles by Monath, T. P
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Medical Bulletin 54:229-241 (1998)
© 1998 The British Council

research-article

Vaccine development against infection with Helicobacter pylori

Harry Kleanthous, Cynthia K Lee and Thomas P Monath

Ora Vax Inc. Cambridge, Massachusetts, USA

Correspondence to: Dr Harry Kleanthous, Ora Vax Inc., 38 Sidney Street, Cambridge, MA 02139, USA

Abstract

Infection with Helicobacter pylori, is one of the most prevalent infections world-wide, where approximately 50% of adults in the developed world and over 90% of inhabitants in the developing world are infected. Chronic infection with H. pylori is the cause of gastritis, peptic ulcer disease and is a risk factor for gastric adenocarcinoma. Recent studies have demonstrated the suitability of an immunization strategy in the prevention and treatment of H. pylori infection, and the potential for management of disease. Mucosal administration of purified recombinant sub-unit proteins of H. pylori, together with a mucosal adjuvant, has identified urease to be highly efficacious in prophylactic and therapeutic animal model studies, and show partial therapeutic activity in humans. Several other antigens are also effective, and the recent sequencing of the H. pylori genome has led to an intensive effort in antigen discovery. Other research has centered on the identification of novel approaches for delivery, and the immunological mechanisms underlying protective immunity. In this review, preclinical data and the results of early-stage clinical trials and directions for future research on Helicobacter vaccines are described.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Infect. Immun.Home page
T. Aebischer, S. Laforsch, R. Hurwitz, F. Brombacher, and T. F. Meyer
Immunity against Helicobacter pylori: Significance of Interleukin-4 Receptor {alpha} Chain Status and Gender of Infected Mice
Infect. Immun., January 1, 2001; 69(1): 556 - 558.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
C. T.K.-H. Stadtlander and J. W. waterbor
Molecular epidemiology, pathogenesis and prevention of gastric cancer
Carcinogenesis, December 1, 1999; 20(12): 2195 - 2208.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
Y ZEVERING, L JACOB, and T F MEYER
Naturally acquired human immune responses against Helicobacter pylori and implications for vaccine development
Gut, September 1, 1999; 45(3): 465 - 474.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.